Acquired Hemophilia in Pediatric Population

Area of Science:

• Pediatrics
• Hematology
• Immunology

Background:

• Acquired inhibitors against factor VIII (FVIII) are rare in nonhemophiliac children but can cause severe bleeding.
• Identifying high-risk pediatric groups is crucial for early diagnosis and management.

Purpose of the Study:

• To investigate the frequency of acquired hemophilia development in high-risk pediatric populations.
• To assess the prevalence of FVIII inhibitors in nonhemophiliac children with specific risk factors.

Main Methods:

• A study involving 483 nonhemophiliac children (aged 2-20 years), including healthy controls.
• Risk groups comprised children with transfusion-dependent β-thalassemia major, malignancy, asthma, type I diabetes, and collagen disorders.
• Inhibitor testing was performed using the Bethesda assay.

Main Results:

• Only two out of 483 children developed acquired FVIII inhibitors.
• The positive cases were a child with solid tumor (osteosarcoma) and a child with type I insulin-dependent diabetes mellitus.
• No inhibitors were detected in other risk groups or healthy controls.

Conclusions:

• Acquired FVIII inhibitors are uncommon in nonhemophiliac children, even in high-risk groups.
• Consider acquired inhibitors in the differential diagnosis of unexplained bleeding in children with risk factors.
• Early detection and management are vital for patients presenting with bleeding episodes and associated risk factors.